FDA Approves Novartis AG (NVS)'s Simbrinza for Glaucoma
4/22/2013 8:32:39 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Alcon, the global leader in eye care and a division of Novartis, has received US Food and Drug Administration (FDA) approval for Simbrinza suspension, indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension. Elevated IOP is the only modifiable risk factor for glaucoma. Glaucoma is a group of eye diseases that lead to progressive damage of the optic nerve and can result in gradual, irreversible loss of vision, and eventually blindness, if left untreated. Simbrinza is a fixed-dose combination medication that offers a wide range of treatment possibilities due to its strong efficacy and ability to decrease elevated IOP by 21- 35 per cent. In addition, it is the only available, fixed-dose combination therapy for glaucoma in the US without a beta blocker.
Help employers find you! Check out all the jobs and post your
comments powered by